More than 224,000 new cases of lung cancer will be diagnosed in 2016. Lung cancer remains the leading cause of cancer deaths, with more people expected to die from lung cancer in 2016 than from breast, prostate, and colon cancers combined. This educational activity will update healthcare professionals’ knowledge regarding risks, screening, diagnoses, and treatment of lung cancer, including palliative symptom management.
The goal of this continuing education module is to update nurses’, advanced practice nurses’, and respiratory therapists’ clinical knowledge of lung cancer. After studying the information presented here, you will be able to:
- Describe three risk factors for lung cancer
- Differentiate between two common types of lung cancer
- Describe three interventions used to treat lung cancer
Beth Eaby-Sandy, MSN, CRNP, OCN, declared she is on the speaker’s bureau for Amgen, Celgene, Eisai and Merck; she has done consulting for AstraZeneca and Clovis. The planners reviewed the content and found it to be free of bias.
This course is intended for multiple professions, including nurses and respiratory therapists.
Respiratory therapists: Take this version of the course to ensure you receive appropriate credit.
This program has been approved for 1 contact hour of Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd., Suite 100, Irving, TX 75063. AARC Sponsor ID: 9514012. This is a non-traditional course. This CE course is approved from 1/17/2012 to 1/17/2014 and 2/17/2014 to 2/17/2016.
If you are a respiratory therapist, remember to give us your AARC member number when filling out your license number information.
OnCourse Learning is also approved by the Florida Board of Respiratory Care (provider #FBN 50-1489).
Course Originally Released on:
Date of Most Recent Review:
Course Termination/Update Date:
Unless stated above, the planners and authors of this course have declared no relevant conflicts of interest that relate to this educational activity. OnCourse Learning guarantees this educational activity is free from bias. There is no commercial or in-kind support provided for this online educational activity.
Please see CE Course Instructions to learn how to earn CE credit for this module. For successful completion of this course, learners must read the course, and complete a posttest and evaluation survey.
This CE activity does not include any unannounced information about off-label use of a product for a purpose other than that for which is approved by the Food and Drug Administration (FDA).
The approval status for this educational activity, granted by the AARC, does not expressly or implicitly confer AARC endorsement of the activity’s content.
This course completion will be electronically reported to CE Broker as required per Florida Statute 456.025(7). Click here to view your CE Broker transcript and check the status of your CE requirements with a FREE 7-day CE Broker trial subscription. It may take up to 24 hours for the course to appear on your CE Broker transcript.